Neurocrine Biosciences (NBIX) has put INGREZZA back in focus after publishing KINECT-PRO Phase 4 results that link once-daily treatment with sustained improvements in tardive dyskinesia symptoms and patient-reported quality of life in real-world settings.

The INGREZZA data arrives after a mixed trading patch for Neurocrine Biosciences, with the share price down 9.6% over 30 days but still showing a 9.9% year to date share price return and a 65.9% five year total shareholder return. This suggests that momentum has been choppy rather than moving in a single direction.

If this kind of specialty pharma story interests you, it can be useful to see what else is moving in related areas by scanning 40 healthcare AI stocks.

Neurocrine Biosciences now trades at a sizeable discount to analyst targets and an even larger gap to some intrinsic value estimates, yet the recent share pullback reflects caution around execution and competition. Is that discount generous or deserved?

Most Popular Narrative: 27.5% Undervalued

The most followed narrative on Neurocrine Biosciences suggests a fair value of about $213 per share, compared with the last close at $154.49, which frames the INGREZZA and CRENESSITY stories in a very different light.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides), and a strong preclinical pipeline, allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Want to see how this pipeline-heavy story translates into that higher fair value? The narrative leans on compounded revenue assumptions, rising margins and a richer earnings multiple. Curious which of those levers does most of the work behind the $213 figure.

Result: Fair Value of $213.13 (UNDERVALUED)

However, the bullish Neurocrine Biosciences narrative still hinges on INGREZZA and CRENESSITY execution, while pricing pressure and higher SG&A could easily challenge those optimistic assumptions.

Another View: What Neurocrine Biosciences' P/E Ratio Is Telling You

The first narrative leans heavily on discounted cash flows and long range forecasts. Yet on a simple P/E basis, Neurocrine Biosciences trades at 22.3x earnings, which is higher than the US biotechs industry at 16.7x and below its own fair ratio of 24.9x. That mix points to some valuation support but also clear risk if sentiment turns. Which signal do you put more weight on: the premium to peers or the gap to the fair ratio investors might move toward?

Next Steps

Given the mixed signals around Neurocrine Biosciences, it makes sense to review the data yourself and decide where you stand while sentiment is still forming. To understand why some investors are optimistic about its potential rewards, take a closer look at the 4 key rewards.

Looking for more investment ideas beyond Neurocrine Biosciences?

If Neurocrine Biosciences has you thinking about what else could belong on your watchlist, use the Simply Wall St Screener to surface focused, data driven stock ideas fast.

• Capture potential mispricing by scanning companies that look attractively valued today through the 53 high quality undervalued stocks.
• Strengthen your defensive side by searching for companies with robust finances using the solid balance sheet and fundamentals stocks screener (50 results).
• Spot lesser known opportunities that still show strong fundamentals with the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.